KPV

Mechanism

Alpha-MSH fragment associated with NF-kB down-regulation and mast-cell stabilization.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

• Mucosal inflammation support
• IBD symptom research
• Post-injury swelling

Reconstitution

mass ÷ diluent = concentration; dose ÷ concentration = volume; volume × the syringe factor = units on the barrel (100 for U-100, 40 for U-40). Run your own numbers.

Half-life, storage & sport

Elimination half-life

not on file — no primary pharmacokinetic study found.

Storage

not on file — no stability record on file.

In sport (WADA 2026)

Prohibited, at all times — S0 catch-all. the list Not named; no therapeutic approval. An alpha-MSH fragment, but not a melanocortin class the list names.

No half-life is on file for this compound, and the figures circulating in its place do not agree with each other. 2 separate accounts are recorded on this page, read from 6 pages between them: 1 to 2 hours, and one more account that names no number at all. No curve is drawn below, because drawing one would mean choosing a winner among them and publishing that choice as though something had measured it. Read what each one says, and where it was read from.

Literature on file 2

• animal in vivo
  PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation (Gastroenterology 2008, cited 111x) graded on: an animal model — read from the indexed abstract — “mice”
• in vitro
  Structural modification of the tripeptide KPV by reductive 'glycoalkylation' of the lysine residue (PLOS ONE 2018, cited 6x) graded on: peptide glycoalkylation chemistry with antimicrobial assays; no biological activity found — read from the abstract — “abstract review”

What is circulated not evidence 8

Claims passed around in community guides and vendor copy, recorded because they circulate — not because they are true. Each is shown with the page it was read from and what this record actually holds. Checked 2026-08-26.

• unverified community data dose ubiquitous contradicts the record

  500 mcg to 1 mg orally once daily on an empty stomach, thirty minutes before food, is the gut protocol given across dosing guides.

  500 mcg – 1 mg

  On the record The record holds 200-500 mcg per administration daily, and marks it unverified. The circulated upper bound of 1 mg is double the maximum on file, and the empty-stomach timing has no counterpart in the record.

  Source 1 · Source 2

• unverified community data titration common nothing on file either way

  A five days on, two days off weekly pattern, inside an eight weeks on and eight weeks off cycle, is the standard schedule stated in guides.

  200 – 500 mcg

  On the record The record holds a cycle of 4 to 8 weeks and nothing else about scheduling. No weekly on/off pattern and no washout interval is on file.

  Source 1

• unverified community data benefit common nothing on file either way

  Oral dosing is justified by the claim that the PepT1 transporter carries KPV into intestinal cells and that PepT1 is upregulated in inflamed gut, making the route self-targeting.

  PepT1 transporter actively imports KPV into intestinal epithelial cells

  On the record The record lists oral and subcutaneous routes, with mucosal inflammation support and IBD symptom research as benefits, but holds no transporter mechanism, no oral bioavailability figure and no half-life. The mechanism circulating as the reason to swallow the dose is not on file at all.

  Source 1 · Source 2

• unverified community data dose occasional nothing on file either way

  Topical KPV at around 7.5 mg twice daily is circulated for skin complaints, and is described in the same source as the least-established route.

  ~7.5 mg (anecdotal)

  On the record Not on file. The record lists only oral and subcutaneous routes for KPV, so the topical route itself has no record, let alone a dose fifteen times the oral maximum on file.

  Source 1

• unverified community data side effect common nothing on file either way

  KPV is presented as having no meaningful side-effect profile, with guides noting only that long-term human safety data is limited.

  no controlled human data

  On the record The record holds no side effects for KPV, and states explicitly that no stability record is on file for storage. It grades the compound at the animal rung, on an animal model read from the indexed abstract. Silence in the record is not a safety finding, and the community reads it as one.

  Source 1

• unverified community data titration common nothing on file either way

  Starting at 200 mcg daily for a week to assess tolerance, then stepping up to 500 mcg, is the titration given in most guides.

  200 – 500 mcg

  On the record The record holds the same 200-500 mcg span as a flat range with no starting point and no step. The endpoints match; the idea that the low end is a tolerance test rather than a dose in its own right is not on file.

  Source 1 · Source 2

• unverified community data half life common nothing on file either way

  A plasma half-life of approximately one to two hours is stated, with anti-inflammatory effects said to last twelve to twenty-four hours.

  Approximately 1-2 hours. However, its anti-inflammatory effects can last longer, typically up to 12-24 hours

  On the record No half-life for KPV is on file, in any species. No page stating this figure cites a measurement, and an equal number of pages say the opposite — that the half-life is minutes rather than hours. One dosage guide states directly that the figure repeated across retail sites has no traceable source.

  Source 1 · Source 2 · Source 3

• unverified community data half life common nothing on file either way

  The plasma half-life is described as minutes rather than hours, reasoned from the tripeptide being cleaved rapidly by peptidases, with local retention in inflamed gut tissue lasting longer than the plasma figure.

  The plasma half-life of KPV is short (minutes), but the local tissue retention in inflamed mucosa is much longer because of PepT1-mediated uptake.

  On the record No half-life for KPV is on file. This is an inference from the molecule's size and its susceptibility to proteases rather than a measurement, and no page stating it reports one. It contradicts the one-to-two-hour figure circulating on the same subject by roughly thirty to a hundred times, and neither camp has a study behind it.

  Source 1 · Source 2 · Source 3

Identity

PubChem CID 125672 computed 3D conformer

Skeletal formulathe canonical depiction

Drawn by PubChem from CID 125672, the identifier on this record.

Molecular weight

402.5

Molecular formula

C16H30N4O4

CAS number

67727-97-3

PubChem CID

125672

InChI key

YSPZCHGIWAQVKQ-AVGNSLFASA-N

Sequence

KPV

SMILES

CC(C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)N

InChI

InChI=1S/C16H30N4O4/c1-10(2)13(16(23)24)19-14(21)12-7-5-9-20(12)15(22)11(18)6-3-4-8-17/h10-13H,3-9,17-18H2,1-2H3,(H,19,21)(H,23,24)/t11-,12-,13-/m0/s1

Classified as

Subcutaneousroute

This is the route the reconstitution arithmetic assumes. Mass divided by diluent volume gives concentration, dose divided by concentration gives volume, and volume in mL multiplied by 100 gives units on a U-100 barrel: 5 mg in 2 mL is 2.5 mg/mL, and 0.25 mg comes out at 0.1 mL, which is 10 units.

Oralroute

Route sets what a milligram means. An oral figure and an injected figure for the same compound are not comparable amounts, and treating one as the other is one of the commonest ways a record gets misread.

Also called

• KPV
• KPV (GI)

Listed prices 258

What 177 shops we track listed for KPV, read from their own public catalogues on 2026-09-14. We take no commission on these and they are not ranked by any payment — how vendors are scored.

Share this record